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ABSTRACT Enterolactone and enterodiol, mammalian lignans derived from dietary sources such as flaxseed, sesame seeds,
kale, broccoli, and apricots, may impede tumor proliferation by inhibiting activation of nuclear factor kappa B (NFjB) and
vascular endothelial growth factor (VEGF). We examined the associations between urinary enterolactone and enterodiol with
prostatic tumor expression of NFjB, VEGF, and Ki67 among 147 patients with prostate cancer who participated in a
presurgical trial of flaxseed supplementation (30 g/day) for *30 days. Urinary enterolignans and tissue biomarkers were
determined by high-performance liquid chromatography and immunohistochemistry, respectively. After supplementation, we
observed significant correlations between intakes of plant lignan and urinary concentrations of total enterolignans (q = 0.677,
P< .0001), enterolactone (q = 0.676, P < .0001), and enterodiol (q= 0.628, P< .0001). Importantly, we observed that total
urinary enterolignans and enterolactone were significantly and inversely correlated with Ki67 in the tumor tissue (q = - 0.217,
P= .011, and q = - 0.230, P = .007, respectively), and a near-significant inverse association was observed for enterodiol (q=
- 0.159, P = .064). An inverse association was observed between enterolactone and VEGF (q = - 0.143, P= .141), although
this did not reach statistical significance. We did not observe an association between enterolignans and NFjB. In conclusion,
flaxseed-derived enterolignans may hinder cancer cell proliferation via VEGF-associated pathways.
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The plant lignans secoisolariciresinol and matair-esinol are present in legumes, cereals, fruits, and
vegetables; however, flaxseed is the richest source of these
phytoestrogens.1 After ingestion, secoisolariciresinol and
matairesinol are converted to the enterolignans, en-
terolactone and enterodiol, via aerobic intestinal microflora.2
There is growing evidence suggesting that enterolactone and
enterodiol may inhibit carcinogenesis. In vitro studies have
shown that enterolignans reduce cancer cell proliferation,
and animal studies have observed that animals fed with diets
containing lignan have fewer tumors and reduced tumor
burden.3 Although fewer in number, several studies in
human populations have supported the anticarcinogenic
properties of enterolignans.4–7
Preclinical studies have shown that enterolignans target
several molecular pathways involved in carcinogenesis.
This includes nuclear factor kappa B (NFjB), a key tran-
scription factor that controls cell growth, angiogenesis, and
inflammatory response, and is frequently activated in cancer
cells. Previous research suggests that enterolignans inhibit
the activation of NFjB.8 A recent investigation reported
reductions in NFjB activation by enterolactone and en-
terodiol with decreased activation of downstream intracel-
lular signaling targets involved in inflammation.9 Further, it
has been suggested that the transition from indolent tumor
growth to more-aggressive tumor proliferation is accom-
panied by the onset of angiogenesis in a process coined, the
angiogenic switch.10 Thus, there is a rationale to hypothe-
size that therapies that inhibit angiogenesis would also
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exhibit anticarcinogenic properties. Studies have reported
that enterolignans are antiangiogenic. In a xenograft breast
cancer mouse model, mice fed a diet supplemented with
flaxseed had reduced tumor production of the proangiogenic
protein, vascular endothelial growth factor (VEGF), com-
pared to mice fed a control diet.11,12 In contrast, there was no
effect of 25 g/day flaxseed supplementation on VEGF se-
cretion in breast tissue from healthy women.13
Another key feature of tumorigenesis is uncontrolled cell
growth.14 A study on patients with postmenopausal breast
cancer consuming 25 g/day flaxseed for 32 days before
surgery found decreased cell proliferation in breast
tumors.15 Expanding on these findings, a previous study
found that a 1-year regimen of 50mg/day of secoisolar-
iciresinol diglucoside significantly reduced breast cell pro-
liferation in premenopausal women at risk for developing
breast cancer.16 Taken together, these data suggest that
flaxseed-derived enterolignans have anti-carcinogenic po-
tential, because they can inhibit inflammation, angiogenesis,
and reduce tumor cell proliferation.
Similar to breast cancer, prostate cancer is a hormone-
related cancer that appears to be responsive to the anticar-
cinogenic effects of lignan. We previously reported that
flaxseed supplementation for *30 days before surgery
significantly reduced the tumor proliferation rates among
men who elected prostatectomy for localized prostate
cancer.17 While these findings were promising, we did not
investigate the molecular targets in the tumor tissue that
were associated with inflammation and angiogenesis.
Therefore, the purpose of this study was to explore the
correlations between dietary intake of lignan, physiologic
enterolignan concentrations, and prostatic tumor tissue
expression of NFjB, VEGF, and Ki67, a marker of cell
proliferation, in this patient population.
This study utilized data from our previous multisite phase
II randomized controlled trial (NCT00049309) in men with
prostate cancer awaiting prostatectomy.17 The trial ran-
domized 161 men by race (Black vs. non-Black) and biopsy
Gleason sum ( ‡ 7 vs. £ 6) to control (n = 41), flaxseed
(FS; n = 40), low-fat diet (LF; n = 40), or FS+LF (n = 40)
for*30 days before surgery. Men assigned to the FS groups
consumed 30 g/day of whole-ground flaxseed; men in the LF
groups consumed < 20% of calories from fat; and the con-
trol group was instructed to maintain their usual diet.17 Pre-
and posturinary enterolignan concentrations and tumor
biomarkers were available from 147 men from the parent
study.
All procedures were approved by the Duke University
Health System, Durham Veteran’s Administration Hospital,
and the University of Michigan Community Clinical On-
cology Program Institutional Review Boards, and written
informed consent was obtained before collection of all
samples and data.
The NCI Diet History Questionnaire (DHQ)18 was ad-
ministered at baseline and follow-up to determine the
background dietary intake of lignans, and we used a pub-
lished database developed by Thompson et al. to estimate
the amount of plant lignan consumed from individual food
items.19 We calculated the total intake of plant lignan pro-
vided by flaxseed supplementation by multiplying the av-
erage grams per day of flaxseed consumed by the amount of
plant lignan in the flaxseed (1 g provided 333 lg of plant
lignan). Flaxseed was provided by ENRECO, Inc. (Mani-
towoc, WI, USA) in one lot (150 kg), and held in a whole-
seed form in cold storage before use. It was analyzed for
lignan content (Laboratory of Alister Muir, Saskatoon Re-
search Center, Saskatoon, Saskatchewan, Canada) at the
beginning and end of the study period, and the values were
averaged.17 The amount of plant lignan from flaxseed was
added to the values of plant lignan that were present in the
diet.
To determine the physiological levels of enterolignans,
participants collected urine over a 24-h period and returned
the refrigerated sample the following day, whereupon it was
aliquotted and stored at - 80C. Urinary enterolignans were
hydrolyzed and quantified via high-performance liquid
chromatography.20 The concentrations of urinary lignans
were corrected for mg/mL of creatinine to adjust for varia-
tions in urinary volume.
As previously described elsewhere,17,21 immunohisto-
chemistry was used to determine the proliferation index
(Ki67; Biocare, Walnut Creek, CA, USA), VEGF (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), and activation
of NFjB (Abcam, Cambridge, MA, USA) from tissue sec-
tions cut from formalin-fixed paraffin-embedded prostatic
tumor blocks. Slides were reviewed and scored by two in-
dependent pathologists who were blinded to randomization
status.17,21
To compare the effects of a diet high in lignans against a
diet not supplemented with a source of dietary lignan on
urinary levels of enterolignans, we combined both flaxseed
groups, that is, flaxseed alone and flaxseed/low-fat diet, into
one group (Flaxseed) and combined the two groups that did
not receive flaxseed, that is, control and low-fat diet (No
Flaxseed). Differences in the baseline characteristics be-
tween the two study groups (Flaxseed vs. No Flaxseed) were
determined using t-tests. Dietary lignan, urinary en-
terolignan, and tissue biomarker data were non-normally
distributed, and attempts at transforming the data did not
improve the distribution; therefore, the median and range
Table 1. Baseline Characteristics of Study Subjects
No FS (n= 74) FS (n = 73)
Age, years 58.5 – 7.43 59.8 – 7.25
Race, % (n)
Caucasian 69% (51) 69% (51)
African-American 22% (16) 25% (18)
Other 9% (7) 6% (4)
BMI, kg/m2 29.1 – 4.2 28.5 – 4.2
Serum PSA, ng/mL 5.8 – 3.54 6.7 – 3.60
Biopsy Gleason score, % (n)
£ 6 91% (67) 89% (65)
‡ 7 9% (7) 11% (8)
Values are given as mean– standard deviation or as percent (number).
BMI, body–mass index; PSA, prostate-specific antigen; FS, flaxseed.
358 AZRAD ET AL.
are presented for these variables. Wilcoxon signed-rank
tests were used to test for differences in change scores for
dietary and urinary lignans. Spearman correlation coeffi-
cients were generated to determine the associations between
dietary lignan, urinary lignan, and tissue biomarkers. JMP
8.0 software (Cary, NC, USA) was used in the analyses; all
P values were 2-sided, and an alpha of < 0.05 was consid-
ered statistically significant.
At baseline, there were no differences in characteristics
between the Flaxseed (n = 73) and No Flaxseed (n = 74)
groups (Table 1). Dietary intake of plant lignan also was
similar across the study groups at baseline, but as expected,
the intake of plant lignan markedly increased in the
flaxseed-supplemented groups over the study period. Si-
milarly, there were no between-group differences in the
concentrations of urinary lignan metabolites at baseline;
however, after flaxseed supplementation, marked increases
in urinary enterolignans were observed in the Flaxseed
group (Table 2). In addition, there was a highly significant
correlation overall between the dietary intake of plant
lignan and urinary excretion of enterolactone (q = 0.676,
P < .0001), enterodiol (q = 0.628, P < .0001), and total en-
terolignans (q = 0.677, P < .0001) in the follow-up time
period.
Correlations between urinary enterolignans and prostate
tumor expression of Ki67, VEGF, and NFjB are shown in
Table 3. Urinary concentrations of enterolactone and total
enterolignan were significantly and inversely associated
with Ki67. However, associations with enterodiol were
weaker. Prostatic tissue expression of VEGF was lower
in patients with higher enterolactone, although this did
not reach statistical significance. In contrast, there was no
apparent correlation between the urinary enterolignans and
NFjB.
In this study, we observed that the total enterolignans and
enterolactone were associated with the antiproliferative ef-
fects in the target tissue, as indicated by a significant inverse
correlation between these plant lignan metabolites and Ki67
staining in prostate tumor tissue. The magnitude of these
associations ranged from modest to moderate in signifi-
cance. There also was a suggestion that higher enterolactone
was associated with hindered tumor angiogenesis by lower
tumor expression of VEGF. Conversely, we observed no
association between enterolignans and reduced activation of
inflammatory pathways in the prostate as manifested by
NFjB activity, a finding consistent with a study by Hey-
mach et al.21 Therefore, these study findings support that
enterolignans, and specifically enterolactone, are likely to
exert chemoprotective effects by hindering cell proliferation
and possibly reduced tumor angiogenesis.
As previously observed in a recent meta-analysis, higher
dietary intake of foods high in plant lignan may reduce the
risk for cancer.4 Similarly, some observational studies,6,7,22
but not all,23 have reported that higher physiological levels
of enterolignans are correlated with a reduced risk for cancer,
improved cancer prognosis, and reduced risk for cancer-
related mortality, suggesting that enterolignans are chemo-
protective. In contrast, earlier studies in preclinical models
suggested that enterolactone may stimulate cell proliferation
in some hormone-sensitive cell lines, including MCF-7
breast cancer cells.24 In the present study, we found no evi-
dence that enterolignans stimulated tumor growth in men
with localized prostate cancer. Indeed, our findings sup-
port the hypothesis that enterolignans are antiproliferative
in vivo. These findings expand on the knowledge regarding
the molecular targets through which these dietary constitu-
ents may exert their antineoplastic potential. Based on our
findings, increased dietary intake of lignans via flaxseed
supplementation significantly increased physiological en-
terolignan concentrations and hindered tumor cell growth.
Prostate cancer is unique in that most cases will remain
indolent, while only some will become virulent. Therefore,
some men will choose active surveillance rather than more
aggressive treatment. Flaxseed supplementation has yet to
be tested in men who choose active surveillance, but based
Table 2. Dietary Intake and Urinary Concentrations of Lignan
No FS (n= 74) FS (n= 73)
Baseline Follow-up Baseline Follow-up Pa
Dietary lignan, lg/day
Lignan 262 (12–1263) 254 (1–777) 282 (59–862) 299,930 (299,720–300,448) < .0001
Urinary enterolignan,b lg/day
Enterolactone 200.7 (1.92–2731.3) 300 (2.52–3892.9) 193.2 (1.94–2787.6) 4731.9 (6.53–233,163.0) < .0001
Enterodiol 34.5 (1.92–2040) 31.7 (2.23–2943) 45.6 (1.57–1046.9) 2724.4 (29.1–36,805.8) < .0001
Total lignan 263.4 (3.85–3046.2) 339.11 (5.30–5079.8) 274.3 (4.35–2810.3) 10,565.3 (150–256,807) < .0001
Values are given as median (range).
aP for change score.
bUrinary enterolignan concentrations adjusted for creatinine.
Table 3. Spearman Correlations Between Urinary
Enterolignans and Prostatic Tumor Biomarkers
NFjB Ki67 VEGF
Enterolactone - 0.109 - 0.230* - 0.143
Enterodiol - 0.117 - 0.159 - 0.07
Total lignan - 0.132 - 0.217* - 0.132
*P< .05.
NFjB, nuclear factor kappa B; VEGF, vascular endothelial growth factor.
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on our findings that it is safe, inexpensive, easy to obtain,
and its metabolic products reduce cell proliferation, flaxseed
supplementation may present an opportunity for future
chemopreventive research. Additional studies using flax-
seed supplementation in this unique patient population are
therefore warranted.
In conclusion, this study provides direct evidence that
dietary intake of plant lignans via flaxseed supplementation
inhibits cancer cell growth and possibly reduces tumor an-
giogenesis in patients with prostate cancer. The consump-
tion of food items, such as flaxseed, which are potential
sources of enterolignans, should be explored further, given
their chemoprotective properties.
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